Lailai Li

Lailai Li

Auto-generated profile, based on publicly available information

Lailai Li

Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2022 in Medicine
Verified
Journal Article
Open access
MCMenglu Mm Chen
Menglu Mm Chen
WLWen Li
Wen Li
LLLailai Li
Lailai Li
YCYihui Chai
Yihui Chai
YYYuqi Yang
Yuqi Yang
XPXiang Pu
Xiang Pu
Background: To prove that serum vitamin D (VD) levels are strongly associated with ankylosing spondylitis (AS) disease activity, the association between serum VD levels and key monitoring indicators of AS disease activity has been analyzed, such as the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). Methods: Studies published in PubMed, Cochrane Library, EMBASE, and China National Knowledge Infrastructure by August 30, 2022 were searched, and 6 studies finally met the selection criteria. Serum 25-hydroxyvitamin D (25(OH)D), ESR, CRP levels, and correlation coefficients between serum VD and BASDAI, ESR, CRP in AS, and control in these studies were extracted for the meta-analysis. Results: When compared to controls, patients with AS had considerably lower blood 25(OH)D levels (MD = −7.53 ng/mL, 95% CI, −9.78 to −5.28, P < .001) and significantly higher ESR and CRP levels (ESR: MD = 11.75 mm/h, 95% CI, 4.20 to 19.31, P = .002; CRP: MD = 15.36 mg/L, 95% CI, 4.95 to 25.77, P = .004). Additionally, a negative correlation was discovered between serum VD levels and BASDAI, ESR, and CRP (Fisher’ Z = −0.34, −0.38, −0.35, respectively). Conclusion: The findings of our meta-analysis demonstrated a negative correlation between serum VD levels and the main monitoring indices of disease activity in patients with AS and verified that the differences in the continent and ethnicity may be one of the major contributors to this finding.

16 July 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Open access
YZYanyan Zhang
Yanyan Zhang
DLDayi Liang
Dayi Liang
LLLailai Li
Lailai Li
YTYilian Tang
Yilian Tang
CZChen Zhang
Chen Zhang
XPXiang Pu
Xiang Pu
Relinqing Granules (RLQ), a single-herb formulation derived from Polygonum capitatum Buch.-Ham. ex D. Don (THL), possesses diverse pharmacological properties-including antimicrobial, anti-inflammatory, and antioxidant activities-which suggest their potential utility in treating pneumonia. This study seeks to elucidate the underlying mechanisms of RLQ to support its future clinical application in managing inflammatory lung diseases. This study aimed to investigate the therapeutic effects of RLQ on pneumonia and elucidate its underlying mechanisms, with a particular focus on the phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/AKT/mTOR) signaling pathway. Pneumonia was induced in mice via lipopolysaccharide (LPS) administration, while A549 cells were similarly stimulated with LPS to establish an in vitro inflammation model. Mice received RLQ treatment by oral gavage for seven consecutive days. Subsequently, lung tissues were collected for hematoxylin-eosin (H&E) staining, enzyme-linked immunosorbent assay (ELISA), Western blotting, and quantitative real-time polymerase chain reaction (qPCR). In vitro, RLQ-treated A549 cells were evaluated through ELISA, Cell Counting Kit-8 (CCK-8), flow cytometry, Western blotting, and qPCR. To further elucidate the underlying mechanism, A549 cell models with mTOR knockdown and overexpression (OE) were constructed to assess the regulatory role of mTOR in inflammation and apoptosis. RLQ alleviated LPS-induced lung inflammation by shifting the regulatory T cell/T helper 17 cell (Treg/Th17) balance toward an immunoregulatory state and modulating pro-inflammatory cytokine expression, potentially through the PI3K/AKT/mTOR signaling pathway. In vitro, RLQ treatment reduced cytokine levels, improved cell viability, and inhibited apoptosis in LPS-injured A549 cells by regulating this pathway and its downstream apoptotic proteins. Furthermore, in mTOR knockdown and OE models, RLQ significantly mitigated LPS-induced cellular damage, enhanced cell viability, and suppressed apoptosis, which correlated with the downregulation of mTOR pathway activation. RLQ effectively protected against LPS-induced lung and alveolar epithelial cell injury by inhibiting PI3K/AKT/mTOR pathway phosphorylation, restoring the Treg/Th17 immune balance, and suppressing apoptosis. These findings provide new mechanistic insights into the therapeutic potential of RLQ in the treatment of pneumonia.

21 June 2024 in Medicine
Verified
Journal Article
Open access
YTYilian Tang
Yilian Tang
XPXiang Pu
Xiang Pu
ZFZhiliang Fan
Zhiliang Fan
XKXiangyan Bd Kong
Xiangyan Bd Kong
CZChen Zhang
Chen Zhang
LLLailai Dd Li
Lailai Dd Li
The present study utilizes network pharmacology and molecular docking methodologies to investigate the mechanism of action behind the intervention of Polygonum capitatum Buch.-Ham.ex D. Don (THL) in treating pulmonary nodules (PN). This research aims to provide a theoretical foundation for broadening the clinical application of THL. Active components of THL were identified and screened through an extensive literature review and the PharmMapper database, followed by an analysis of their target interactions. Relevant targets associated with PN were selected using databases such as OMIM and GeneCards, with an intersection of the two sets being determined. STRING11.5 facilitated the acquisition of protein-protein interaction data, which was then imported into Cytoscape 3.7.2 to establish a protein interaction network topology. This enabled the identification of pivotal targets affected by THL intervention in PN. The study further employed the Metascape database to conduct GO and KEGG bioinformatics enrichment analyses, which illuminated core pathways involved in THL’s therapeutic effects on PN. A comprehensive component-target-pathway diagram was constructed utilizing Cytoscape 3.7.2 software, with molecular docking validations carried out via Maestro software. A total of 49 active THL ingredients were discerned, implicating 67 PN-relevant targets. Subsequent software analysis pinpointed 10 key targets, including ALB, EGFR, and SRC. Molecular docking studies indicated strong binding affinities for most protein-compound pairs, with 44 out of 60 docking results exhibiting binding energies below −5 kcal/mol. Enrichment analysis highlights that key targets are mainly involved in pathways such as cancer, lipid metabolism and atherosclerosis, estrogen signaling, IL-17 signaling, complement and coagulation cascades, and chemical carcinogenesis through receptor activation. Through comprehensive network pharmacological approaches, this research delineates the synergy of THL’s multiple components, targets, and pathways in mitigating PN. It posits that primary active ingredients of THL – quercetin, salidroside, and oleanolic acid – may exert effects on targets like ALB, EGFR, SRC, potentially modulating pathways associated with cancer, lipid and atherosclerosis, and IL-17 signaling in the context of PN intervention.

14 June 2024 in Medicine
Verified
Journal Article
Open access
SCShunhuan Ba Chen
Shunhuan Ba Chen
DZDongyan Ba Zhai
Dongyan Ba Zhai
YLYuan Ba Li
Yuan Ba Li
YTYong Ba Tan
Yong Ba Tan
XTXiaoke Ba Tang
Xiaoke Ba Tang
LLLailai Li
Lailai Li
This study aims to analyze the effective components of Polygonum capitatum (PC) inhibiting Escherichia coli based on network pharmacology methods and predict its molecular mechanism of action. PC compounds and targets were collected from the TCMSP database, Swiss Target Prediction, and the literature. E coli targets were searched using the GeneCards database. The targets of E coli and the targets of the active ingredients of PC were taken as intersections to obtain the intersecting targets. The resulting overlapping targets were uploaded to the STRING database to construct the protein interaction network diagram of E coli target inhibition. The key targets for the inhibitory effect of PC on E coli were obtained. Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed by uploading key targets into the DAVID database. The results showed that there were 50 targets for PC to inhibit E coli. Among them, there are 5 core targets, mainly including AKT1, TNF, EGFR, JUN, and ESR1. A total of 196 gene ontology functional analysis results and 126 Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis results were obtained. These include cellular response to cadmium-ion, cellular response to reactive oxygen species, pathways in cancer, prostate cancer, and PI3K-Akt signaling pathway. Molecular docking results indicate that Lutedin, Hirsutin, Flazin, and Ellagic acid in PC have high affinity for the target genes AKT1, TNF, MAPK3 and EGFR. PC exerts its inhibitory effect on E coli through multi-targets and multi-pathways, which provides a new basis for the new use of PC as an old medicine.

17 October 2025 in Medicine
Verified
Journal Article
Open access
YCYihui Chai
Yihui Chai
NLNa Li
Na Li
DZDongyan Zhai
Dongyan Zhai
SCShunhuan Chen
Shunhuan Chen
YLYuan Li
Yuan Li
LLLailai Li
Lailai Li
Numerous studies have confirmed that Tongmai Yangxin pill (TMYXP) is effective in the treatment of coronary heart disease (CHD) with a deficiency of both Qi and Yin in traditional Chinese medicine theory, but whether it works through the regulation of gut microflora (GM) for the treatment of the disease is unclear. The network pharmacology and molecular docking were used to explore the potential mechanism of TMYXP in treating CHD by regulating GM. Based on network pharmacology, the potential target of TMYXP in the treatment of CHD by GM was identified. The network diagram of protein–protein interaction was established to screen the key targets. The biological function and enrichment pathways of TMYXP were analyzed using the DAVID database, and the biological pathway of TMYXP in treating CHD by regulating GM was explored. The key active ingredients and proteins were analyzed through molecular docking simulation. TMYXP may regulate 27 targets and related 34 types of intestinal bacteria to exert cardiovascular protection, with the active substance basis including 145 active ingredients represented by Quercetin and Luteolin. GM plays an important role in the treatment of CHD with TMYXP, whose therapeutic mechanism relates to multi-target and multi-pathway.